In 2015, Avista Pharma Solutions formed through Accuratus Lab Services’ and its owner Ampersand Capital Partners’ acquisition of the chemistry, manufacturing and controls (CMC) operations of Array BioPharma based in Longmont, Colorado.
The firm has since invested in the site, and this week announced the completion of an upgrade which doubles Avista’s active pharmaceutical ingredient (API) capacity.
“This expansion enables us to respond more efficiently for existing clients and also to serve clients who require larger deliveries by adding both additional reactors and scale,” an Avista spokesperson told this publication.
“We’re also now able to process potent compounds, increasing the scope of customers we can serve.”
In total, Avista Pharma now has seven GMP API manufacturing suites and four non-GMP manufacturing suites at the site, with a maximum scale of 200 liters.
The capacity expansion is part of a broader investment of over $20m, we were told, upgrading manufacturing and testing capabilities across all its sites during the last two years.
The firm, has a GMP manufacturing facility in Durham, North Carolina added from the acquisition of Scynexis’ CMO business in 2015, and microbiology, sterility testing, and microbial ID services in Massachusetts from the $4m acquisition of Microtest Labs earlier this year.